81 results
424B5
CELU
Celularity Inc - Ordinary Shares
28 Jul 23
Prospectus supplement for primary offering
4:24pm
, incurred an in-process research and development impairment charge of approximately $108 million and we are currently evaluating the potential impact … research and development and other expenses related to our ongoing operations. Investment in biopharmaceutical product development is highly speculative
424B5
nedxo6q
6 Apr 23
Prospectus supplement for primary offering
9:03pm
8-K
EX-99.1
0o0au
10 Nov 22
Celularity Reports Third Quarter 2022 Financial Results and Provides Corporate Update
4:19pm
424B5
zqd b6sp4u93k9ar
15 Sep 22
Prospectus supplement for primary offering
4:06pm
424B5
oduhhtmnq99tj
8 Sep 22
Prospectus supplement for primary offering
8:46am